Immunome, Inc. IMNM 深 沪
已收盘 07-02 16:00:00 美东时间
23.61
+2.120
+9.87%
华盛通- 最 高23.67
- 今 开21.60
- 成交量 186.97万股
- 最 低 21.26
- 昨 收 21.49
- 总市值 26.74亿
- 52周最高 27.65
- 市盈率 静 --
- 换手率 1.65%
- 52周最低 7.96
- 委 比 -68.14%
- 总股本 1.13亿
- 历史最高 63.78
- 量 比 0.72
- 振 幅 11.21%
- 历史最低 2.09
- 每 手 1
- 风险率 5.26%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Immunome director Isaac Barchas disposes of 201,050 common shares worth $4.4 million
Immunome director Isaac Barchas disposes of 201,050 common shares worth $4.4 million Immunome director Isaac Barchas disclosed sales of 201,050 common shares on June 30 and July 2. Shares sold at weighted average prices of $21.12, $22.35, $23.33. Indirect holdings reported at 208,504 shares followin
07-03 08:32
Tango Therapeutics Appoints Robert Azelby to Board of Directors
Tango Therapeutics appoints Robert Azelby to its Board of Directors. With over 30 years of biopharmaceutical leadership, Azelby brings expertise in oncology commercialization and corporate strategy. His addition coincides with the advancement of vopimetostat, a potential PRMT5 inhibitor for pancreatic cancer, toward late-stage development. Azelby's experience will support Tango's mission to transform care for patients with MTAP-deleted cancers.
06-22 20:05
FACTBOX-Major deals involving US drugmakers and biotechs over the past decade
FACTBOX-Major deals involving US drugmakers and biotechs over the past decade Adds AbbVie deal June 22 (Reuters) - AbbVie ABBV.N has agreed to buy biotech Apogee Therapeutics APGE.O for $10.9 billion in cash, as the U.S. drugmaker builds its next-generation immunology pipeline. The move adds to a gr
06-22 19:46
美股大行评级 | Adobe惨遭18家大行下调目标价！CFRA首予SpaceX(SPCX)"卖出"评级，目标价115美元
今日重点评级关注：Piper Sandler：维持Tenax Therapeutics"超配"评级，目标价从20美元升至50美元；Tigress Financial：维持优步"买入"评级，目标价从110美元升至115美元
06-15 08:32
Wedbush Reiterates Outperform on Immunome, Maintains $31 Price Target
Wedbush analyst David Nierengarten reiterates Immunome (NASDAQ:IMNM) with a Outperform and maintains $31 price target.
06-12 22:04
Immunome宣布IM-1617 ADC一期临床完成首例患者给药
生物技术公司Immunome周三宣布，其潜在首创新药(first-in-class)抗体偶联药物IM-1617的一期临床试验已完成首例患者给药。该药物针对一...
06-11 22:26
Immunome Does First Participant In Its Phase 1 IM-1617 Study To Treat Solid Tumors
Immunome, Inc. (NASDAQ:IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced that the first patient has been dosed in the Phase 1, first-in-human trial of IM-1617, a potential first-in-class ADC directed at an undisclosed s...
06-11 19:32
Immunome doses first patient in Phase 1 trial of IM-1617 solid-tumor ADC
Immunome doses first patient in Phase 1 trial of IM-1617 solid-tumor ADC Immunome dosed the first patient in a Phase 1, first-in-human study of IM-1617, an antibody-drug conjugate for advanced solid tumors. No clinical results have been presented; the trial will assess safety and early signs of anti
06-11 19:30
FACTBOX-Major deals involving US drugmakers and biotechs over the past decade
FACTBOX-Major deals involving US drugmakers and biotechs over the past decade Adds GSK deal June 9 (Reuters) - GSK GSK.L has agreed to buy cancer drug developer Nuvalent NUVL.O for $10.6 billion in its biggest deal in years, as the British drugmaker looks to bolster its pipeline and support long-ter
06-09 17:13
Immunome says FDA reviews varegacestat NDA for desmoid tumors
Immunome says FDA reviews varegacestat NDA for desmoid tumors Immunome filed an NDA with the FDA in April 2026 for varegacestat to treat progressing desmoid tumors. EMA marketing application submission is planned by end-2026. Disclaimer: This news brief was created by Public Technologies (PUBT) usin
05-30 20:00
